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Background/aim: Stigma has a high incidence and adversely affects people with diabetes. In this context, patients face difficulties such
as fear of losing their jobs, travel restrictions, isolation from social life, problems related to mental health, and feeling of wellness. The
aim of this study was to investigate the validity and reliability of the stigma assessment scale in individuals with type 2 diabetes.
Materials and methods: The study sample consisted of 153 diabetic individuals. The validity of language, content, and construct were
examined to evaluate the validity of the type 2 diabetes stigma assessment scale. Cronbach’s alpha was used to assess internal consistency
reliability.
Results: The content validity index of 19 items which were detected as significant was found to be 0.86. The Cronbach’s alpha coefficient
of the scale is 0.92. The results of the item analysis show that all factor loads are significant (t-value > ±1.96). The coefficient of correlation
between type 2 diabetes stigma assessment scale and test–retest technique was 0.82.
Conclusion: It was concluded that the stigma assessment scale is a valid and reliable measurement tool in individuals with type 2
diabetes mellitus. Nurses may use this tool to better understand and help relieve the prevalence and severity stigma of individuals with
type 2 diabetes in Turkey.
Key words: Type 2 diabetes, nursing, stigma, validity

1. Introduction
Diabetes mellitus (DM) is a chronic disease that requires
complex continuous medical care, in which many risk
factors can be controlled through glycemic control.
According to the 2019 data of the International Diabetes
Federation, there are 463 million people with diabetes
worldwide. Turkey has the highest prevalence of diabetes
among European countries and is predicted to be among
the top 10 countries with the highest number (11.2
million) of people with diabetes in 2045 [1]. The results
of the TURDEP-II study conducted in 15 provinces in
Turkey identified that the prevalence of diabetes reached
13.7% in the Turkish adult population [2].
In Turkish, the word ‘stigma’ means wound, black mark,
indignity, disgrace and labelling. Prejudice, which is the
basis of stigma [3,4], is a premature judgment of a person,
object, or subject without an investigation. Judgment can
be either positive or negative, and people’s behaviors are
affected by prejudice. Ultimately, stigma resulting from
prejudices leads to the exclusion and discrimination
of people. Discrimination is the deprivation of certain

rights and interests of people or groups in society due
to stigmatization and prejudices. There are two types of
stigma: imposed stigma is the actual rejection experience
based on the inability of healthy/unhealthy individuals
to be accepted into the social community. Perceived
(internalized) stigma refers to the shame of healthy/
unhealthy individuals about having stigmatized disease
and the fear of being exposed to stigmatization [5–7].
Stigma in the Turkish society with type 2 diabetes is
a concept that is ignored and not emphasized. Age, sex,
education, occupation, marital status, social class, culture,
religious beliefs, information about the disease, contact
with mental illness, psychological type, and mass media
are all factors affecting stigma. Studies have investigated
the relationship between stigma and tuberculosis, obesity,
epilepsy, and many mental chronic diseases [8–10]. Diabetes
is a chronic disease that is very common in the community.
Stigma has a high incidence and adversely affects people
with diabetes. In a study, it was determined that diabetic
patients with stigma had poor self-management and blood
glucose control [11]. The stigma experienced by patients
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with type 2 diabetes affects their sense of self-worth, their
attitude toward social participation, and self-management
[12]. In addition, patients with type 2 diabetes who
received intensive insulin therapy were found to have high
stigma experiences [13].
Browne et al. [14] recognized this condition and
evaluated the stigma with type 2 diabetes stigma assessment
scale (DSAS-2) developed specifically for diabetes.
Therefore, we aimed to adapt this scale because there is
no measurement tool to measure such a phenomenon in
Turkish society.
2. Materials and methods
2.1. Design and study sample
This study sought to characterize the validity and reliability
of the type 2 diabetes stigma assessment scale, which
was developed by Browne et al. [14], for Turkish society.
Permission was obtained from the relevant author via
e-mail, and a research protocol was established according
to the author’s wishes. Data was collected from January
2018 to June 2018.
2.2. Statistical analysis
The data of this study were analyzed using SPSS Statistics
version 21.0 (IBM, Armonk, NY, USA). Sociodemographic
and clinical characteristics were described as frequencies,
means ± standard deviations.
The distributive normality of the variables was
investigated by the Shapiro–Wilk test because of the
number of units. The convenience of a scale for factor
analysis and the suitability of the data are evaluated by
Kaiser–Meyer–Olkin (KMO) and Bartlett tests. K-20
coefficients were used to investigate the reliability of
the scales. The internal consistency of the scale was
measured by Cronbach’s alpha and test–retest reliability
was measured using intraclass correlation coefficient.
Spearman’s correlation coefficient was used to investigate
the relationships between the variables not normally
distributed. The scales were evaluated with Pearson’s
correlation analysis using the concurrent validity method.
A level of p < 0.05 was taken to indicate significance.
2.3. Data form
An introductory form for diabetic individuals consisted of
questions about sex, age, educational status, occupation,
economic status, and the year of diagnosis of diabetes.
2.3.1. The type 2 diabetes mellitus stigma assessment scale
The scale was developed by Browne et al. [14] and consists of
three dimensions, including different behaviors (6 items),
blame and judgment (7 items), and self-stigmatization (6
items), with a total of 19 items. It is a 5-point Likert-type
scale that is scored according to the selection between
“strongly disagree” and “absolutely agree”. It consists of
1

three dimensions, including different behaviors (items
1, 4, 7, 10, 14, 17 and possible range, 6–30), blame and
judgment (items 2, 3, 5, 8, 12, 16, 19 and possible range,
7–35) and self-stigmatization (items 6, 9, 11, 13, 15, 18 and
possible range, 6–30). The total stigma score of the scale
is between 19 and 95 points. Higher scores correspond to
higher levels of stigmatization [14].
2.3.2. The Rosenberg self-esteem scale
The Rosenberg self-esteem scale (RSES) was developed in
1965 by Rosenberg. The validity and reliability study of the
Turkish version was carried out by Cuhadaroglu in 1986,
and the Cronbach’s alpha internal consistency coefficient
was found to be 0.71. In this study, Cronbach’s alpha
internal consistency coefficient of the Rosenberg selfesteem scale was found to be 0.77. The scale consists of
12 subscales and 63 items. The section, which is a Likerttype assessment scale, consists of 10 items. According
to the internal assessment system of the scale, subjects
receive scores between 0 and 6 points. The total score
obtained from the scale shows high self-esteem from 0 to
1, moderate self-esteem from 2 to 4, and low self-esteem
from 5 to 6. Higher scores correspond to lower levels of
self-esteem1. The Rosenberg self-esteem scale is used for
concurrent validity. The validity stages and translation of
the scale consisted of the following steps.
2.4. Translation
In the first phase, three individuals from the translation
team translated the scale from English to Turkish. The
two experts whose native language is English and who
can speak Turkish then back-translated the scale from
Turkish into English. Finally, two Turkish language
experts evaluated the compatibility of this scale with the
Turkish language, and the comprehensibility of the scale
was pretested.
2.5. Content validity
For the validity of the scale, expert opinions were
consulted for the items of the scale and the items were
evaluated according to the Lawshe technique. Factor
analysis was used for the analysis of the structure validity.
Factor analysis in behavioral sciences is applied in order
to reveal structure(s) covered by the items of the scale.
These structures are defined as the factors of the scale. The
convenience of a scale for factor analysis and the suitability
of the data are evaluated using the Kaiser–Meyer–Olkin
(KMO) and Bartlett tests. The KMO test determines
whether the distribution is sufficient for factor analysis, and
results from 0.80 to 0.90 are considered very satisfactory.
Bartlett’s test determines whether the hypothesis that the
correlation matrix is equal to the unit matrix is accepted
or rejected. The rejection of the hypothesis means that
the correlation coefficient among the variables is different

Cuhadaroglu F. Self esteem in adolescents. Hacettepe University Faculty of Medicine, Unpublished Specialty Thesis, Ankara, 1986.
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from 1.00 and that the measured variable is multivariate for
the universe parameter. In order to determine the content
validity index of the type 2 DM stigma assessment scale,
expert opinions were consulted. By assessing the views
from a total of 12 experts, the content validity ratio (CVR)
was calculated for each item. Subsequently, the content
validity index (CVI) was determined by calculating
the mean of the calculated CVRs. This index is used to
determine the decision of experts on the necessity of each
item. This value is calculated for the level of eligibility
of the items. Since there were twelve experts, it was
concluded that items with a CVR value greater than 0.56
met the content validity [15–18]. After the calculation of
the CVRs, it was determined that all items of the scale were
considered eligible by experts. The content validity index
of 19 items that were statistically significant was found to
be 0.86. In addition, the result of the Kaiser–Meyer–Olkin
(KMO) test for sampling adequacy was found to be 0.911
(>0.60) for the established diabetes scale.
2.6. Concurrent validity
For criterion validity, the relationship of scale scores with
one or more external criteria is analyzed. This method
can be applied as either concurrent (convergent validity,
compliance validity, current validity) validity or predictive
validity. In concurrent validity, the relationship with,
if any, a previously developed scale measuring the same
conceptual structure or, if not, with a scale developed using
different scales measuring similar or related concepts is
examined [15,19].
There is no scale that measures the concept of stigma
in patients with type 2 diabetes in Turkey. Therefore, the
nearest RSES scale was used. In our study, the relationship
between the DSAS-2 and the RSES was evaluated with
Pearson’s correlation analysis using the concurrent validity
method. There was a statistically significant relationship

between the total scores of the RSES and stigma scales (p <
0.05). This relationship was found to be weak and positive
(r = 0.337). Increases in the Rosenberg scale corresponded
with increases in the stigma scale (Table 1).
2.7. Test–retest reliability
In the item analysis, test–retest reliability means that a scale
gives consistent results between two applications; that is,
the scale shows invariance over time [18]. The DSAS-2 was
performed 10 days after the first application, and the test–
retest correlation was 0.82 (p ≤ 0.001). Item 5 was found
to have the lowest test–retest correlation, whereas item 14
was found to have the highest correlation (Table 2).
There was a statistically significant relationship
between scores of the different behaviors and the blame
and judgment subscales (p < 0.05), which was found to be
strong and positive (r = 0.766); that is, as the score of the
different behaviors’ subdimension increases, the score of
the blame and judgment subdimension will also increase.
In addition, there was a statistically significant relationship
between scores of subscales of the self-stigmatization and
the different behaviors (p < 0.05), which was found to be
moderately strong and positive (r = 0.721). There was also
a statistically significant relationship between scores of the
self-stigmatization and the blame and judgment subscales
(p < 0.05), which was found to be strong and positive (r
= 0.768); that is, as the score of the self-stigmatization
subdimension increases, the score of the blame and
judgment subdimension will also increase. The scores
of subscales of the stigma and the different behaviors
were also strongly and positively related (p < 0.05; r =
0.7889); that is, higher total scores of the dimensions of
the stigma scale correspond with higher scores of the
different behaviors’ subdimension. There was a statistically
significant relationship between the total scores of the
stigma scale dimensions and the score of the blame and

Table 1. Correlation test results for relationship between Rosenberg self-esteem scale and stigma scale scores.
Scales

Correlations
Treated
differently

Blame and judgement
Self-stigma
Total DSAS-2
Rosenberg

1304

Blame and
judgement

Self-stigma

Total DSAS-2

r

0.766**

p

0.001

r

0.721**

0.768**

p

0.001

0.001

r

0.889**

0.938**

0.903**

p

0.001

0.001

0.001

r

0.211**

0.321**

0.406**

0.337**

p

0.001

0.001

0.001

0.001
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Table 2. Test–retest correlations.
Item

Factor

Test–retest
correlation*

1. Bazı insanlar, tip 2 diyabetim olduğu için sorumluluklarımı (örn. iş, aile) yerine
getiremeyeceğimi düşünüyorlar.

Treated differently

0.56

2. Sağlık profesyonelleri, tip 2 diyabetim olduğu için benimle ilgili olumsuz yargılarda
bulunuyorlar.

Blame and judgement

0.64

3. Bazı insanlar, tip 2 diyabetim olduğu için şimdi veya geçmişte fazla kilolu olmam
gerektiğini varsayıyorlar.

Blame and judgement

0.47

4. Bazı insanlar, tip 2 diyabetim olduğu için bana “hasta” veya “rahatsız”mışım gibi
davranıyorlar.

Treated differently

0.58

5. Tip 2 diyabeti olan bireylerin etrafında suçlama ve utanç var.

Blame and judgement

0.34

6. Tip 2 diyabetim olduğu için, kendimi mahcup hissediyorum.

Self-stigma

0.62

7. Tip 2 diyabetim olduğu için ayrımcılığa maruz kaldım.

Treated diffrently

0.56

8. Sağlık profesyonelleri, tip 2 diyabeti olan kişilerin kendilerine bakamayacağını düşünüyor. Blame and judgement

0.59

9. Tip 2 diyabetim olduğu için utanıyorum.

Self-stigma

0.45

10. Bazı insanlar, tip 2 diyabetim olduğu için beni daha az değerli buluyorlar.

Treated diffrently

0.63

11. Tip 2 diyabetim olduğu için, kendimi yetersiz hissediyorum.

Self-stigma

0.55

12. Tip 2 diyabetin, bir ‘yaşam tarzı” hastalığı olduğu yönünde olumsuz bir etiketleme var.

Blame and judgement

0.49

13. Tip 2 diyabetli olmak, bana başarısızmışım gibi hissettiriyor.

Self-stigma

0.65

14. Bazı insanlar yiyecek/içecek içeren sosyal birlikteliklerden uzak durmam gerektiğini
düşündükleri için beni dışlıyorlar.

Treated differently

0.72

15. Tip 2 diyabetim olduğu için kendimi suçlu hissediyorum.

Self-stigma

0.68

16. Tip 2 diyabetim olmasının benim kendi hatam olduğu söylendi.

Blame and judgement

0.64

17. Tip 2 diyabetim olduğu için başkaları tarafından (örn. arkadaşlarım, iş arkadaşlarım, özel
Treated differently
ilişkim) reddedildim.

0.62

18. Tip 2 diyabetim olduğu için kendimi suçluyorum.

Self-stigma

0.57

19. Tip 2 diyabetim olduğu için, bazı insanlar yemek seçimlerimi eleştiriyorlar.

Blame and judgement

0.59

* Spearman correlation test

judgment subdimension (p < 0.05), and this relationship
was also found to be very strong and positive (r = 0.938).
As the score of the stigma scale increases, the score of the
blame and judgment subdimension will also increase.
There was a statistically significant relationship between
total scores of the dimensions of the stigma scale and the
self-stigmatization subscale (p < 0.05). This relationship
was found to be very strong and positive (r = 0.903) (Table
1). As the total scores of the dimensions of the stigma scale
increases, the self-stigma subscale scores also increase.
2.8. Ethical considerations
The ethical approval of this study was obtained from the
Ethical Committee for Clinical Trials of Ankara Yıldırım
Beyazıt University (Protocol number: 2017/39). Before
the study, written informed consent was obtained from all
patients with type 2 diabetes mellitus.

3. Results
3.1. Sample characteristics
The study population consisted of type 2 diabetes mellitus
patients between 18 and 75 years of age who were
admitted to a training and research hospital in Ankara
and who had no communication problems and were able
to speak and understand Turkish. The data of the study
were collected between March and September 2018. The
number of patients in the sample should be 5 to 10 times
the number of items in the validity and reliability studies
[15]. Therefore, it was planned to include 200 patients for
DSAS-2 with 19 items. The sample of the study consisted of
153 patients with type 2 diabetes who agreed to participate
in the study. Of the diabetic subjects who participated in
this study, 55.19% were female. The rate of patients with
16 or more years of diagnosis was 20.13%. Among these
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individuals, 49.35% were primary school graduates, and
40.26% were housewives. The mean HbA1c levels of the
sample were 7.34 ± 2.11.
3.2. Construct validity
After providing the language and content validities of
the scale, confirmatory factor analysis was performed to
determine construct validity and whether an overlap was
detected between the original structure of the scale and the
factor structures. The factor structure of the scale is shown
in Figure.
The compliance indices were found as X2/sd = 1.871,
RMR = 0.055, RMSEA = 0.075, CFI = 0.971, and GFI =

Figure. Path diagram of DSAS-2.
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0.96, respectively [15–18]. An analysis of the coefficients
showing the relationship between the observed variables of
the model representing the factorial structure showed that
all coefficients were adequate. Considering the compliance
statistics calculated by CFA, the previously determined
structure of the scale adapts highly to the collected data.
The results obtained from the analysis show that the factor
structure is generally within acceptable limits (Figure). This
situation shows that the model determined theoretically
in Figure corresponds to the sample data. The analysis
of the significance test results for the path coefficients
given in Table 3 shows that all factor loads are significant
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Table 3. Regression and t-values of DSAS-2.
Factor
Treated differently
Treated differently
Treated differently
Treated differently
Treated differently
Treated differently
Blame and judgement
Blame and judgement
Blame and judgement
Blame and judgement
Blame and judgement
Blame and judgement
Blame and judgement
Self-stigma
Self-stigma
Self-stigma
Self-stigma
Self-stigma
Self-stigma

İtems

Regression values

a17

0.779

a14

0.751

9.863

a10

0.736

9.599

a7

0.806

10.748

a4

0.669

8.596

a1

0.691

8.922

a19

0.558

5.592

a16

0.425

4.62

a12

0.576

5.679

a8

0.543

5.448

a5

0.797

6.972

a3

0.59

5.775

a2

0.492

5.061

a18

0.589

7.760

a15

0.6

9.07

a13

0.852

7.846

a11

0.681

7.03

a9

0.738

7.093

a6

0.72

7.374

Table 4. Cronbach’s alpha conclusions on the reliability of
subscales.
Cronbach’s alpha

n

Rosenberg self-esteem scale

0.72

10

Treated differently

0.87

6

Blame and judgement

0.777

7

Self-stigma

0.847

6

Total DSAS-2

0.927

19

(t-value > ±1.96). In addition, according to standardized
parameter estimations, it is concluded that all indicators
are in conformity with the relevant structure and are of the
correct mark and size. All estimates for coefficients were
significant (p < 0.05).
3.3. Internal consistency reliability
For the reliability analysis of the scale, Cronbach’s alpha
analysis (internal consistency analysis), an item analysis
(item-total correlation, corrected item-total correlation
and item discrimination indexes) and a test–retest
technique were used. Cronbach’s alpha analysis assesses
whether the items on the scale are consistent with each
other and whether they measure the same characteristic.

t-values

In other words, Cronbach’s alpha analysis is a measure of
the internal consistency and homogeneity of the items on
the scale (higher Cronbach’s alpha coefficients correspond
with more reliable scales) [15,18]. The analysis of the
reliability dimension of the scale showed that Cronbach’s
alpha coefficient for the reliability of items of the different
behaviors subscale was 0.87. Cronbach’s alpha coefficient
for the reliability of items of the blame and judgment
subscale was 0.78, and for the reliability of items of the
self-stigmatization subscale, it was 0.85. In addition,
Cronbach’s alpha coefficient for the reliability of items
of the stigma scale was 0.92. A coefficient greater than
0.70 indicates that the scale is reliable. Cronbach’s alpha
coefficient for the reliability of items of the Rosenberg
scale was 0.72. Note that coefficient values greater than
0.70 indicate that the scale is reliable (Table 4).
4. Discussion
The present study investigated the validity and reliability
of the stigma assessment scale for patients with type
2 diabetes in Turkish society, and the obtained results
demonstrate a high level of validity and reliability. This
is an important scale that is easily applicable in Turkish
society and therefore needs to be considered in further
research. In Turkey, there is a dominance of the traditional
social structure. Therefore, individuals with chronic
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diseases (especially cancer, diabetes, AIDS, and TBC) can
be perceived differently by society or individuals; thus,
the perception of stigmatization may occur. Due to the
absence of a scale for assessing the stigma associated with
diabetes in Turkey, this study is of particular importance.
In this study, confirmatory factor analysis (CFA) was
used to evaluate the factor structure of the developed
diabetes scale and to determine the items that were valid
in the measurement model. The results obtained show that
the factor structure is generally within acceptable limits.
The results also show that the three-dimensional factorial
structure of the scale provides adequate compliance
values. These results support the results found in studies
carried out at the stage of development of the original scale
[13]. The three-factor structure, which corresponds to the
original scale and includes the dimensions of ‘different
behaviors’, ‘blame and judgment’ and ‘self-stigmatization’
has been confirmed.
According to the analysis of the compliance indices,
it was decided that the original structure of the scale was
highly compatible with the collected data. This result can
be regarded as evidence that the scale is eligible for Turkish
society.
In our study, the relationship between the DSAS-2
and RSES scales was evaluated with Pearson’s correlation
analysis using the concurrent validity method. There was
a statistically significant positive relationship between
total scores of the RSES scale and the DSAS-2 total scale
score and subscale scores (p < 0.05). The same relationship
was found in the study by Browne et al. [14]. In addition,
many studies have found that stigmatization is strongly
and consistently associated with negative psychological
conditions such as depression, anxiety, anger, low selfesteem, and demoralization [20–23]. In a study on cancer
patients, it was found that stigmatization decreased the
quality of life of patients and negatively affected emotional
functions [22]. In another study on people with diabetes,
it was found that diabetes-related stigma has a significant
effect on psychological distress, depressive symptoms, and
self-esteem [24]. Similarly in another study, it was observed
that people with diabetes tried to hide their diseases [25].
These results can be regarded as an indicator that stigma is
as important as other psychosocial concepts.
In addition, Cronbach’s alpha coefficient for the
reliability of items of the stigma scale was 0.93. In the
original scale developed by Browne et al. [14], Cronbach’s
alpha coefficient, which is a measure of the reliability of the
scale, was found to be 0.95. These results, in analogy with
the original scale, show that the DSAS-2-Turkey scale also
has a high reliability value. In this study, Cronbach’s alpha
coefficient of the scale and its subdimensions showed that
they all have high levels of reliability: 0.87 for the different
behavior subdimensions, 0.77 for the blame and judgment
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subdimension, and 0.85 for the self-stigmatization
subdimension. Although similar results were obtained,
Cronbach’s alpha coefficient of the blame and judgment
and self-stigmatization subscales was significantly higher
in the Browne et al.’s [14] study (0.90).
In this study, the reliability coefficient of the test–retest
test was found to be 0.86 (p = 0.001). Moreover, item 5 was
found to have the lowest test–retest correlation, whereas
item 14 was found to have the highest correlation. The low
correlation coefficient of item 5 in the blame and judgment
subdimension can be attributed to individual variations of
the disease perception. The highest correlation coefficient
of 14 items questioning the area of different behaviors
can be attributed to tabooing and exaggerating nutrition
by individuals with diabetes due to their disease and
thus to the dominance of the idea of exclusion in social
environments.
5. Conclusion
We conclude that the Turkish version of the DSAS-2,
which is composed of 19 questions, is a valid and reliable
scale. Stigma in type 2 diabetes patients is a new concept
in Turkey, and no measurement tool is available for it.
Diabetes is a chronic condition that places a significant
emotional and social burden on the person living with it;
yet, the social aspects of diabetes remain underresearched.
Type 2 diabetes stigma assessment scale will enable nurses
to become aware of the importance of stigma. With
continual use of the DSAS-2, the degree of stigma will
be accurately assessed. As a result of these assessments,
it would be possible to provide patients with different
treatment strategies and nursing care in addition to early
intervention to help reduce stigma. Clinical nurses/
diabetes nurses would support the patients whose stigma
levels were determined. With continual use of the DSAS-2
in diabetic patients, the degree of stigma will be accurately
assessed.
However, further work is needed to provide
psychological support for stigma, to plan appropriate
training programs, and to aid participation of family
members in these trainings to provide further support to
diabetic patients. Finally, we recommend the use of DSAS2 for carrying out cross-cultural research that evaluates
stigma.
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